Nondialyzable uremic toxins

Blood Purification

Volumn 35, Issue SUPPL.2, 2013, Pages 30-41

  Piroddi, Marta ^a   Bartolini, Desireé ^a   Ciffolilli, Silvia ^a   Galli, Francesco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

AGEs; Dialysis; Glycation; Inflammation; Nitric oxide; Oxidative stress; Protein damage; Proteomics; Reactive oxygen species; Uremia; Uremic toxins

Indexed keywords

3 DEOXYGLUCOSONE; 4 HYDROXYNONENAL; ANTIOXIDANT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; CD40 ANTIGEN; CYSTEINE; FIBRINOGEN; GLUCURONIDE; GLYOXAL; HIPPURIC ACID; HOMOCYSTEINE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; INDICAN; INDOLEACETIC ACID; INTERLEUKIN 6; LACTOFERRIN; LEPTIN; MALONALDEHYDE; METHYLGLYOXAL; PENTOSIDINE; PHENOL DERIVATIVE; POLYAMINE; REACTIVE OXYGEN METABOLITE; UREMIC TOXIN; PLASMA PROTEIN; PROTEOME;

ADSORPTION; ANTIOXIDANT ACTIVITY; ARTICLE; ARTIFICIAL KIDNEY; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG BINDING; HUMAN; LIGAND BINDING; MOLECULAR WEIGHT; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; CLINICAL PROTOCOL; IMMUNOBLOTTING; TAXONOMY; UREMIA;

AGING; BLOOD PROTEINS; HUMANS; INFLAMMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; UREMIA;

EID: 84877852792     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000350846     Document Type: Article

References (89)

1. Baurmeister U, Vienken J, Ward RA: Should dialysis modalities be designed to remove specific uremic toxins? Semin Dial 2009; 22:454-457.
2. Vanholder R, Argiles A, Beige J, Brunet P, Drueke TB, Fliser D, Herget-Rosenthal S, Horl WH, Jorres A, Perna A, Rodriguez-Por-tillo M, Spasovski G, Stegmayr B, Stenvinkel P, Wanner C, Wiecek A, Massy ZA: Conservative treatment of the uremic syndrome. Semin Dial 2009; 22:449-453.
3. Ward RA: Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005; 16:2421-2430.
4. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Lat-scha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Steg-mayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934-1943.
5. Yavuz A, Tetta C, Ersoy FF, D'Intini V, Ratanarat R, De Cal M, Bonello M, Bordoni V, Salvatori G, Andrikos E, Yakupoglu G, Levin NW, Ronco C: Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18: 203-211.
6. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins-update 2009. Semin Dial 2009; 22:334-339.
7. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23:1258-1270.
8. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G: An update on ure-mic toxins. Int Urol Nephrol 2013; 45:139-150.
9. Kouoh F, Gressier B, Luyckx M, Brunet C, Dine T, Cazin M, Cazin JC: Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco 1999; 54:695-699.
10. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011; 24:327-337.
11. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A: Oxidative stress and inflammation: implications in uremia and hemodialysis. Clin Biochem 2011; 44:1189-1198.
12. Galli F: Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant 2007; 22(suppl 5):v20-v36.
13. Oberg BP, McMenamin E, Lucas FL, Mc-Monagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009-1016.
14. Vanholder R, Meert N, Schepers E, Glorieux G: Uremic toxins: do we know enough to explain uremia? Blood Purif 2008; 26:77-81.
15. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T: Protein-bound uremic toxins in hemodi-alysis patients measured by liquid chromatog-raphy/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 2012; 403:1841-1850.
16. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ: Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16:1471-1485.
17. Chiappetta G, Corbo C, Palmese A, Galli F, Piroddi M, Marino G, Amoresano A: Quantitative identification of protein nitration sites. Proteomics 2009; 9:1524-1537.
18. Piroddi M, Palmese A, Pilolli F, Amoresano A, Pucci P, Ronco C, Galli F: Plasma nitropro-teome of kidney disease patients. Amino Acids 2011; 40:653-667.
19. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on bio-markers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79:914-919.
20. Ghuman J, Zunszain PA, Petitpas I, Bhat-tacharya AA, Otagiri M, Curry S: Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005; 353:38-52.
21. Schepers E, Glorieux G, Vanholder R: The gut: the forgotten organ in uremia? Blood Pu-rif 2010; 29:130-136.
22. Galli F: Interactions of polyphenolic compounds with drug disposition and metabolism. Curr Drug Metab 2007; 8:830-838.
23. Smith KS, Lee CL, Ridlington JW, Leonard SW, Devaraj S, Traber MG: Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids 2003; 38:813-819.
24. Galli F, Floridi AG, Floridi A, Buoncristiani U: Accumulation of vitamin E metabolites in the blood of renal failure patients. Clin Nutr 2004; 23:205-212.
25. Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC: Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004; 19:3068-3077.
26. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E: The antioxidant properties of serum albumin. FEBS Lett 2008; 582:1783-1787.
27. Thornalley PJ, Rabbani N: Protein damage in diabetes and uremia-identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiologi-cal effect. Free Radic Res 2011; 45:89-100.
28. Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A: Mass spectromet-ric monitoring of albumin in uremia. Kidney Int 2000; 58:2228-2234.
29. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zin-graff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304-1313.
30. Himmelfarb J, McMonagle E: Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60:358-363.
31. Alvarez B, Carballal S, Turell L, Radi R: Formation and reactions of sulfenic acid in human serum albumin. Methods Enzymol 2011; 473:117-136.
32. Faure P, Troncy L, Lecomte M, Wiernsperger N, Lagarde M, Ruggiero D, Halimi S: Albumin antioxidant capacity is modified by methylglyoxal. Diabetes Metab 2005; 31:169-177.
33. Matsuyama Y, Terawaki H, Terada T, Era S: Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 2009; 13:308-315.
34. Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, Valentina V, Libetta C, Galli F: Circulating levels and dietary intake of the advanced glycation end-product marker car-boxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr 2011; 21:329-339.
35. Mitrogianni Z, Barbouti A, Galaris D, Siamo-poulos KC: Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract 2009; 113:c234-c240.
36. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M: The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005; 334:1322-1328.
37. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Tomita K, Otagiri M: Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 2005; 28:973-980.
38. Michelis R, Kristal B, Snitkovsky T, Sela S: Oxidative modifications impair albumin quantification. Biochem Biophys Res Commun 2010; 401:137-142.
39. Sezer MT, Akin H, Demir M, Erturk J, Aydin ZD, Savik E, Tunc N: The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients. J Nephrol 2007; 20:196-203.
40. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002; 61: 2240-2249.
41. Bito R, Hino S, Baba A, Tanaka M, Watabe H, Kawabata H: Degradation of oxidative stress-induced denatured albumin in rat liver endo-thelial cells. Am J Physiol Cell Physiol 2005; 289:C531-C542.
42. Ogasawara Y, Namai T, Togawa T, Ishii K: Formation of albumin dimers induced by exposure to peroxides in human plasma: a possible biomarker for oxidative stress. Biochem Biophys Res Commun 2006; 340:353-358.
43. Terawaki H, Yoshimura K, Hasegawa T, Mat-suyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T, Era S: Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004; 66:1988-1993.
44. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND: Glutathione metabolism and its implications for health. J Nutr 2004; 134:489-492.
45. Giustarini D, Milzani A, Dalle-Donne I, Rossi R: Red blood cells as a physiological source of glutathione for extracellular fluids. Blood Cells Mol Dis 2008; 40:174-179.
46. Canestrari F, Buoncristiani U, Galli F, Gior-gini A, Albertini MC, Carobi C, Pascucci M, Bossu M: Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin Chim Acta 1995; 234:127-136.
47. Galli F, Rovidati S, Benedetti S, Buoncristiani U, Covarelli C, Floridi A, Canestrari F: Over-expression of erythrocyte glutathione S-transferase in uremia and dialysis. Clin Chem 1999; 45:1781-1788.
48. Himmelfarb J, McMenamin E, McMonagle E: Plasma aminothiol oxidation in chronic hemo-dialysis patients. Kidney Int 2002; 61: 705-716.
49. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Des-camps-Latscha B: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21:845-853.
50. Massy ZA, Fumeron C, Borderie D, Tuppin P, Nguyen-Khoa T, Benoit MO, Jacquot C, Buisson C, Drueke TB, Ekindjian OG, Lacour B, Iliou MC: Increased plasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: a prospective study. J Am Soc Nephrol 2004; 15:470-476.
51. Giustarini D, Rossi R: Plasma S-nitrosothiols and chronic renal failure. Am J Physiol Renal Physiol 2004; 287:F1294; author reply F1294-F1295.
52. Ferraro B, Galli F, Frei B, Kingdon E, Cane-strari F, Rice-Evans C, Buoncristiani U, Davenport A, Moore KP: Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Int 2003; 63: 2207-2213.
53. Souza JM, Peluffo G, Radi R: Protein tyrosine nitration-functional alteration or just a bio-marker? Free Radic Biol Med 2008; 45:357-366.
54. Galli F, Piroddi M, Annetti C, Aisa C, Floridi E, Floridi A: Oxidative stress and reactive oxygen species. Contrib Nephrol 2005; 149:240-260.
55. Piroddi M, Depunzio I, Calabrese V, Mancu-so C, Aisa CM, Binaglia L, Minelli A, Butter-field AD, Galli F: Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007; 32:573-592.
56. Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Jacob HS, Eaton JW, Balla G: Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal 2007; 9:2119-2137.
57. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, Szentmiklosi J, Mehes G, Cson-ka T, Smith A, Vercellotti GM, Balla G, Balla J: Red cells, hemoglobin, heme, iron, and ath-erogenesis. Arterioscler Thromb Vasc Biol 2010; 30:1347-1353.
58. Piroddi M, Pilolli F, Aritomi M, Galli F: Vitamin E as a functional and biocompatibility modifier of synthetic hemodialyzer membranes: an overview of the literature on vitamin E-modified hemodialyzer membranes. Am J Nephrol 2012; 35:559-572.
59. Floridi A, Antolini F, Galli F, Fagugli RM, Flo-ridi E, Buoncristiani U: Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17:871-878.
60. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, Buoncristiani E, Floridi A: The effect of PMMA-based protein-leaking dialyzers on plasma homocyste-ine levels. Kidney Int 2003; 64:748-755.
61. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA: Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Ami-no Acids 2003;25:437-444.
62. Piroddi M, Depunzio I, Calabrese V, Mancu-so C, Aisa CM, Binaglia L, Minelli A, Butter-field AD, Galli F: Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007;32:573-592.
63. Galli F: Amino acid and protein modification by oxygen and nitrogen species. Amino Acids 2012; 42:1-4.
64. Requena JR, Levine RL, Stadtman ER: Recent advances in the analysis of oxidized proteins. Amino Acids 2003; 25:221-226.
65. Galli F, Benedetti S, Floridi A, Canestrari F, Piroddi M, Buoncristiani E, Buoncristiani U: Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005; 67: 750-759.
66. Miyata T, Sugiyama S, Saito A, Kurokawa K: Reactive carbonyl compounds related uremic toxicity ('carbonyl stress'). Kidney Int 2001; 78(suppl):S25-S31.
67. Rabbani N, Thornalley PJ: Glycation research in amino acids: a place to call home. Amino Acids 2012; 42:1087-1096.
68. Rabbani N, Thornalley PJ: Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 2012; 42:1133-1142.
69. Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R, Thornalley PJ: Glyca-tion of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 2011; 60:1973-1980.
70. Calcerrada P, Peluffo G, Radi R: Nitric oxide-derived oxidants with a focus on peroxyni-trite: molecular targets, cellular responses and therapeutic implications. Curr Pharm Des 2011; 17:3905-3932.
71. Massari J, Tokikawa R, Medinas DB, Angeli JP, Di Mascio P, Assuncao NA, Bechara EJ: Generation of singlet oxygen by the glyoxal-peroxynitrite system. J Am Chem Soc 2011; 133:20761-20768.
72. Miyata T, Sugiyama S, Suzuki D, Inagi R, Ku-rokawa K: Increased carbonyl modification by lipids and carbohydrates in diabetic ne-phropathy. Kidney Int 1999; 71(suppl):S54-S56.
73. Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, Valentina V, Libetta C, Galli F: Circulating levels and dietary intake of the advanced glycation end-product marker car-boxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr 2011; 21:329-339.
74. Stadtman ER, Levine RL: Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003; 25:207-218.
75. Heffron SP, Parastatidis I, Cuchel M, Wolfe ML, Tadesse MG, Mohler ER 3rd, Ischi-ropoulos H, Rader DJ, Reilly MP: Inflammation induces fibrinogen nitration in experimental human endotoxemia. Free Radic Biol Med 2009; 47:1140-1146.
76. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, Stamer S, Liebler DC, Koliakos G, Heijnen HF, Fitzgerald GA, Weisel JW, Ischiropoulos H: Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 2008; 283:33846-33853.
77. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, Weisel JW, Ischiropou-los H: Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 2004; 279:8820-8826.
78. Thornalley PJ, Rabbani N: Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009; 22:400-404.
79. Santoro A, Guadagni G: Dialysis membrane: from convection to adsorption. NDT Plus 2010; 3:i36-i39.
80. Meyer TW, Peattie JW, Miller JD, Dinh DC, Recht NS, Walther JL, Hostetter TH: Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 2007; 18:868-874.
81. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19:863-870.
82. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatogra-phy/tandem mass spectrometry. J Chro-matogr B Analyt Technol Biomed Life Sci 2010; 878:2997-3002.
83. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW: Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22:1769-1776.
84. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spec-trometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1662-1668.
85. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs1993; 17:809-813.
86. Buoncristiani U, Galli F, Benedetti S, Errico R, Beninati S, Ghibelli L, Floridi A, Canestrari F: Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes. Contrib Nephrol 1999; 125: 133-158.
87. Galli F, Beninati S, Benedetti S, Lentini A, Canestrari F, Tabilio A, Buoncristiani U: Polymeric protein-polyamine conjugates: a new class of uremic toxins affecting erythro-poiesis. Kidney Int 2001; 78(suppl):S73-S76.
88. Noce A, et al: Erythrocyte glutathione trans-ferase: a new biomarker for hemodialysis adequacy, overcoming the Kt/V(urea) dogma? Cell Death Dis 2012;3:e377.
89. Dessi M, et al: Erythrocyte glutathione trans-ferase: a potential new biomarker in chronic kidney diseases which correlates with plasma homocysteine. Amino Acids 2012;43:347-354.